The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Characterization of KRASG12C inhibitor olomorasib single-agent and combination with activity in KRASG12C-mutant models
Open accessAbstract
The impact of first-generation covalent KRAS G12C inhibitors has been reduced due to the development of drug resistance, tolerability and challenges combining with immunotherapy. We designed olomorasib, a next-generation GDP-binding KRAS G12C inhibitor, for nanomolar potency as well as selectivity over wild-type inhibition. In both in vitro and in vivo models of KRAS G12C -mutant cancers, olomorasib reduces RAS activity and pERK levels, leading to substantial and significant tumor growth inhibition. Additionally, olomorasib combined with immune checkpoint inhibitors demonstrates greater anti-tumor activity compared to monotherapy. Furthermore, we demonstrate that olomorasib binds tightly to KRAS G12C even in the presence of clinically relevant second site mutations, a known mechanism of resistance and limitation to currently approved KRAS G12C inhibitors. These findings suggest that olomorasib could be effective for patients with KRAS G12C mutant cancers either as monotherapy or in combination with immunotherapy. Olomorasib monotherapy and combination treatments are currently being investigated clinically.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The publisher hasn’t deposited this paper’s reference list.
Cited by
Kano, Y. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27135796
Chaft, J. E., Lee, J. M., Senan, S., Neal, J. W., Nadal, E., Negrao, M. V., Popat, S., Garassino, M. C., Gray, J. E., Lee, S., et al. (2026) · Future Oncology · doi:10.1080/14796694.2026.2736401
Metadata
- Authors
- Peng, S., Zhang, Y., Lin, X., Si, C., Van Horn, R. D., Dempsey, J. A., Goetz, E., Evans, R. J., Farber, A., Vandekopple, M. J., Ming, W., Gao, H., Yu, C., Xu, W. G., Brown, N. E., Dowless, M. S., Pulliam, N., Barda, D. A., Guo, D., Boulet, S. L., Huber, L., Capen, A., Jones, B., Bogner, S., Castanares, M. A., Stephens, J. R., Johnson, M. A., Curtis, C. L., Strelow, J. M., Xiao, J., Ballard, J., Bocchinfuso, W. P., Chalmers, M. J., Wang, J., Hendle, J., Saflor, M. D., Lagutan, D. M., Gheyi, T., Sarkar, A., Kearins, M., Tung, F., Ho, J., Rodgers, L., Benach, J., Frommelt, A. J., Zhou, L., Ackermann, B. L., McCann, D., Klippel, A., Buchanan, S. G., Henry, J. R., & Gong, X.
- Affiliations
- Eli Lilly (United States) (US)
- Corresponding author
- Gong, Xueqian
- ORCID
- Venue
- Nature Communications
- Published
- 2026-05-04
- Volume
- 17
- Issue
- 1
- ISSN
- 2041-1723 (ISSN-L)
- OpenAlex
- W7160046545
- Cited by
- 1
- References
- 0
- Citations by year
- 2026: 1
- FWCI
- 2.05
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor, 66 d)
- Locations
- Nature Communications (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- KRAS G12C inhibitors, covalent inhibitors, drug resistance, second-site mutations, immune checkpoint inhibitors, combination immunotherapy, ERK1/2 phosphorylation, tumor growth inhibition
- MeSH terms
- Immune Checkpoint Inhibitors, Animals, Antineoplastic Agents, Humans, Mutation, Proto-Oncogene Proteins p21(ras), Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Characterization of KRASG12C inhibitor olomorasib single-agent and combination with activity in KRASG12C-mutant models. https://app.cochat.ai/papers/10.1038/s41467-026-72650-y
- The paper
- Peng, S., Zhang, Y., Lin, X., Si, C., Van Horn, R. D., Dempsey, J. A., Goetz, E., Evans, R. J., Farber, A., Vandekopple, M. J., Ming, W., Gao, H., Yu, C., Xu, W. G., Brown, N. E., Dowless, M. S., Pulliam, N., Barda, D. A., Guo, D., . . . Gong, X. (2026). Characterization of KRASG12C inhibitor olomorasib single-agent and combination with activity in KRASG12C-mutant models. Nature Communications. https://doi.org/10.1038/s41467-026-72650-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.